

November 12, 2021

To,

## **Department of Corporate Service BSE Limited**,

Registered Office: Floor 25, P. J. Towers.

Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.

T: 2272 1233 / 1234 | F : 2272 3121 / 3719 | www.bseindia.com

Subject

: Approval of Standalone Un-Audited Financial Results for the guarter

and half year ended September 30, 2021.

Reference: Centenial Surgical Suture Ltd. | Scrip Code: 531380

Dear Sir.

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure -Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the guarter and half year ended September 30, 2021.
- 2). Statement of Assets and Liabilities for the half year ended September 30, 2021.
- 3). Statement of Cash Flow for the half year ended September 30, 2021.
- 4). Limited Review Report for the guarter and half year ended September 30, 2021.

You are requested to kindly take the same on your record.

Sincerely.



MAHIMA BATHWAL

For CENTENIAL SURGICAL SUTURE LTD. Digitally signed by MAHIMA BATHWAL Date: 2021.11.12

16:28:48 +05'30'

**Mahima BATHWAL Company Secretary & Compliance Officer** 

Enclosures: as mentioned above.

### Registered Office F-29, MIDC, Murbad, Thane 421401. MAHARASHTRA. C912524222905 Fax 912524222905

■ Manufacturing Facility B-17 / F-29 / F-22 MIDC, Murbad, Thane 421401. MAHARASHTRA. 2524223200 Fax 912524 222872

Sales Office - Mumbai 1<sup>st</sup> Floor, Palai Complex CHS Ltd., Bhandarkar Road, Matunga (East) Mumbai 400019. MAHARASHTRA. \$912224102876 Fax 912224161261

☐ Sales Office - Bengaluru No.12/42, Udhani Layout, Off. Cambridge Road, Halasur, Bengaluru 560008. KARNATAKA. **4** 9180 25577791 Fax 9180 25577792

Sales Office - Kolkata Flat No. N-1, Ground Floor, 385, Purbachal, Kalitala Road, P.S.Kasba, Kolkata 700078. WEST BENGAL. 91 3324844875 Fax 91 3324844875




## Statement of Standalone Un-Audited Financial Results for the Quarter and Half year ended September 30, 2021

(Rs. In Lakhs, unless otherwise stated)

		Quarter ended			Half Year ended		Year ended
Sr. No.	Particulars	30-09-2021	30-06-2021	30-09-2020	30-09-2021	30-09-2020	31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	1192.89	837.28	813.66	2030.16	1416.04	3693.30
II	Other Income	0.20	0.02		0.22	0.47	9.26
[1]	Total Revenue (I+II)	1193.08	837.29	813.66	2030.38	1416.51	3702.56
IV	Expenses:	1133.00	057125				
	(a) Cost of Materials Consumed	479.77	267.83	375.79	747.60	703.36	1581.21
	(b) Purchases of Stock-in-Trade	-	-	-			-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	42.02	45.73	(288.37)	87.75	(561.57)	(544.79)
	(d) Employee Benefits Expense	298.75	245.23	238.87	543.98	462.93	997.98
	(e) Finance Costs	45.52	45.41	44.98	90.93	70.11	201.68
	(f) Depreciation and Amortisation Expense	40.53	36.54	43.79	77.07	82.15	155.08
	(q) Other Expenses	252.81	186.09	345.85	438.90	585.45	1158.41
	Total expenses (IV)	1159.39	826.83	760.91	1986.22	1342.42	3549.57
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	33.69	10.46	52.74	44.15	74.09	152.99
VI	Exceptional Items	33.03	10,10	JEST 1			-
VII	Profit / (Loss) after Exceptional items and Tax (V-VI)	33.69	10.46	52.74	44.15	74.09	152.99
VIII	Tax Expense :	33.03	10.10	JE IF , I	1.11.25	1 1197	/
• 111	(1) Current Tax	8.57	2.91	13.71	11.48	19.26	54.00
	(2) Deferred tax	0.57	-	1001	-		2.81
	Total Tax Expenses	8.57	2.91	13.71	11.48	19.26	56.81
IX	Profit / (Loss) for the period form Continuing Operations (VII -VIII)	25.12	7.55	39.03	32.67	54.82	96.18
X	Profit / (Loss) from Discontinuing Operations	25.12	7.55	33.03	JEIO	27104	30.10
XI	Tax expenses of Discontinuing Operations	-	-	-			-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-					
	Profit / (Loss) for the period (IX+XII)	25.12	7.55	39.03	32.67	54.82	96.18
XIV		LJ.IL	1.55	33.03	JE.O.	31.02	30.10
Alv	A. (I) Items that will not be reclassified to profit or loss			-	-		-
XIII	(ii) Income tax relating to items that will not be reclassified to profit or loss			-	-		
	B. (I) Items that will be reclassified to profit or loss	-					-
	(ii) Income tax relating to items that will be reclassified to profit or loss		400				
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss)	25.12	7.55	39.03	32.67	54.82	96.18
VIII	The same was a second of the same second of the sam						
XVI	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83	364.83	364.83
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	10.00	10.00
XVI						10.00	10.00
AVI	(a) Basic	0.69	0.21	1.07	0.90	1.50	2.64
-	(b) Diluted	0.69	0.21	1.07	0.90	1.50	2.64
200		0.00	0.2.1	1.01	0.30	1.50	2.01
XVII	(a) Basic	-		-		_	
	(b) Diluted	-			2.0	-	-
				N. D.			
Alx		0.69	0.21	1.07	0.90	1.50	2.64
	(a) Basic	3.03	OIL I	1.07	0.50	1.50	2.04

www centenialindia co





#### Notes:

- The above Statement of Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2021 ("Statement") is, as reviewed and recommended by the Audit Committee, considered and approved by the Board of Directors at its meeting held on November 12, 2021.
- The Statement is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and other accounting principles generally accepted in India.
- The Statement is subjected to 'limited review' by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion in Limited Review of the Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2021.
- The Management has identified the reportable segments in accordance with the requirements of IND AS-108 "Operating Segments", and decided that the Company has only one reportable business segment "Medical Devices".
- The Company has considered internal and external information upto the date of approval of the Statement in assessing the recoverability of financial and non-financial assets. based on which it expects to recover the carrying amount of these assets. The eventual outcome of impact of global health pandemic may be different from those estimated as on the date of approval of these Statement.
- The previous period figures have been regrouped / rearranged wherever necessary to make it comparable with the current period.
- The COVID-19 situation continues to evolve. The Company has evaluated the impact of this pandemic on its business operations, liquidity and financial position and based on management's review of current indicators and economic conditions, no additional adjustment is required in the financial results for the quarter and half year ended September 30, 2021. Given the uncertainty associated with its nature and duration, the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor any material changes to future economic conditions.
- The Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2021 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.

MURBAD

THANE +· C

for and on behalf of the Board of Directors of

TENIAL SURGICAL SUTURE LTD.

Vijay MAJREKAR Managing Director & Chief Executive Officer

DIN: 00804808

Place: Mumbai, Maharashtra Date: November 12, 2021



## Statement of Assets and Liabilities

Rs. In Lakhs

	Double doub	As at	As at	
	Particulars	September 30, 2021	March 31, 2021	
1	ASSETS			
1)	Non-current assets			
	a) Property, Plant and Equipment	831.87	896.61	
	b) Capital work-in-progress			
	c) Other Intangible assets	0.87	0.70	
	d) Financial assets			
	(i) Loans			
	(ii) Other financial assets	30.76	30.76	
	e) Deferred tax assets (net)	The second second		
	f) Income-tax assets (net)	11.79	1.27	
	g) Other non-current assets	14.09	14.09	
	Total Non-current assets (1)	889.38	943.43	
2)	Current assets			
	a) Inventories	3,421.99	3623.21	
	b) Financial assets	1000		
	(i) Trade receivables	2,297.94	2240.12	
	(ii) Cash and cash equivalents	67.61	53.86	
	(iii) Bank balances other than (ii) above			
	(iv) Loans			
	(v) Other current financial assets	0.89	0.69	
	c) Other current assets	144.64	143.19	
	Total Current assets (2)	5,933.06	6061.07	
	TOTAL ASSETS (I = 1 + 2)	6,822.44	7004.50	
11	EQUITY & LIABILITIES	design flexible and the second		
1)	Equity			
	a) Equity Share capital	542.43	542.43	
	b) Other Equity	2,447.35	2,414.68	
	Total Equity (1)	2,989.78	2957.11	
2)	Liabilities			
	Non-current liabilities		The second second	
	a) Financial Liabilities	Made because the found		
ME	(i) Other financial liabilities	891.02	880.09	
9	b) Long-term provisions		-	
	c) Deferred tax liabilities (net)	17.14	17.14	
part 1	Total Non-current liabilities	908.16	897.23	
2	Current liabilities			
1-1-	a) Financial Liabilities	January of the same		
To he	(i) Trade payables	836.17	1057.54	
	(ii) Other current financial liabilities	2,026.95	2048.24	
43	b) Other current liabilities	61.39	44.38	
	c) Short-term provisions	V. I		
	Total Current liabilities	2,924.51	3150.16	
	Total Liabilities (2)	3,832.66	4047.39	
	TOTAL EQUITY AND LIABILITIES ( II = 1 + 2 )	6,822.44	7,004.50	

www.centenialindia.com | ISO 9001:2015 / ISO 13485:2016 certified company





## Cash Flow Statement for the Quarter and Half Year ended September 30, 2021

Rs. In Lakhs

Particulars	As at September 30, 2021	As at March 31, 2021	
A. Cash flow from operating activities			
Net Profit before tax	44.16	152.99	
Adjustments for :			
Depreciation and amortisation expense	77.07	155.08	
Interest income	(0.22)	(0.59)	
Reclassification on account of adoption of Ind AS 116	- 1	-	
Profit on redemption of mutual funds (net)			
Exchange gain	(2.23)	(8.67)	
Provision for Leave encashment	-	-	
Provision for Gratuity		14.09	
Sundry balances written back/written-off			
Operating profit before working capital changes	118.78	312.90	
Adjustments for :			
Decrease / (Increase) in inventories	201.22	(403.37)	
Decrease / (Increase) in trade receivable	(57.83)	95.19	
Decrease / (Increase) in financials and non-financial assets	(10.72)	22.34	
Decrease / (Increase) in other assets and receivables	(1.45)	22.46	
(Decrease) /Increase in trade and other payables	(214.73)	2.44	
Cash generated from operations	35.29	51.96	
Income tax refund / (paid)	(11.48)	(56.81)	
Net cash (used in) / generated from operating activities	23.81	(4.84)	
B. Cash flow from investing activities			
Acquisition of fixed assets and capital work in progress	(12.50)	(83.84)	
Proceeds from sale of investments	icitization		
Interest income on fixed deposits and other advances	2.45	(4.83)	
Net cash (used in) / generated from investing activities	(10.06)	(88.67)	
C. Cash flow from financing activities			
Proceeds from issuance of Debentures	-		
Proceeds from Short term borrowings	- 3	75.08	
Net cash (used in) / generated from financing activities	- 0	75.08	
Net (decrease) / increase in cash and cash equivalents (A+B+C)	13.75	(18.43)	
Cash and cash equivalents as at the beginning of year	53.86	72.29	
Cash and cash equivalents at the end of year	67.61	53.86	
Components of cash and cash equivalents (Also, refer note 10)			
Cash in hand	3.73	1.90	
Balance with scheduled banks in current accounts	63.88	51.96	
Total	67.61	53.86	

www.centenialindia.com | ISO 9001; 2015 / ISO 13485; 2016 certified company



# Mahesh Chandra & Associates Chartered Accountants

Independent Auditor's Review Report on the Quarter and Half year ended September 30, 2021 Standalone Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors of
CENTENIAL SURGICAL SUTURE LTD.

Registered Office: F-29, M.I.D.C., Murbad, Thane 421401. MAHARASHTRA.

- a. We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of Centenial Surgical Suture Limited ("the Company") for the quarter and half year ended September 30, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No: CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- b. This "statement" which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on November 12, 2021 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- c. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Mahesh Chandra & Associates

Chartered Accountants, Firm Registration No.: 112334W

Per RAJESH BOHRA

Partner ~ Membership No.102587 UDIN: 21102587AAAANO6245

Date: November 12, 2021 Place: Mumbai, MAHARASHTRA.